news
Tiny antibody component could treat or prevent SARS-CoV-2
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
List view / Grid view
Therapeutics
article
Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
news
Two drug candidates show promise against COVID-19 in organoid system
Following their success in organoid systems, two drug candidates are now to be administered to ferrets and tested against COVID-19.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
news
Treatments for macrophage activation syndrome could reduce COVID-19 mortality
Researchers suggest possible therapies for macrophage activation syndrome (MAS), a feature of cytokine storm and a major cause of death in severe COVID-19 patients.
news
Nanobody could be used as antiviral treatment against COVID-19
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
news
Researchers suggest IgA antibodies are better at neutralising SARS-CoV-2
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
news
AI holds promise to accelerate drug repurposing for COVID-19
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
news
Drug candidate outperforms remdesivir as COVID-19 antiviral in cell assays
A compound called BOLD-100, which has shown efficacy against COVID-19 in pre-clinical trials, has now outperformed remdesivir in a cytopathic effect assay.
news
Machine learning reveals potential COVID-19 therapeutic compounds
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
news
Potential COVID-19 treatment and vaccine combination shows success in cells
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
news
Apilimod small molecule shows potent inhibition of SARS-CoV-2 in cells
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
news
Decoy ACE2 receptors show promise as COVID-19 treatment in cell cultures
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
news
Protease inhibitors with antiviral activity against coronaviruses developed
Researchers have created compounds called 3C-like protease inhibitors which demonstrated antiviral activity against several coronaviruses in cells, including COVID-19.
news
Functioning lung cell assay for modelling COVID-19 infections developed
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.